Table 3.
Changes in the expression profile of genes differentiating keratinocyte cultures exposed to LPS and Adalimumab compared to the controls (p < 0.05; −2.0 < FC> +2.0 at least in one comparison).
| mRNA | H_2 vs C | H_8 vs C | H_24 vs C |
|---|---|---|---|
| HRH1 | +2.99 ± 0.15 | +3.54 ± 0.26 | +3.41 ± 0.13 |
| HRH3 | +2.11 ± 0.26 | +2.18 ± 0.11 | +1.74 ± 0.29 |
| HNMT | +5.66 ± 0.81 | +4.85 ± 0.64 | +4.99 ± 0.41 |
| HTR6 | +2.01 ± 0.54 | +3.66 ± 0.34 | +3.74 ± 0.22 |
| GABRB1 | −2.65 ± 0.31 | −2.44 ± 0.08 | +1.04 ± 0.07 |
| GABRB3 | −1.78 ± 0.09 | −3.07 ± 0.17 | −2.98 ± 0.14 |
| EDN1 | −2.36 ± 0.25 | −2.01 ± 0.62 | −2.04 ± 0.26 |
| EDNRA | +7.01 ± 0.48 | −2.14 ± 0.09 | −2.99 ± 0.33 |
| ADA | +5.22 ± 0.25 | +4.14 ± 0.18 | +4.08 ± 0.24 |
| DRD2 | +2.14 ± 0.29 | +1.41 ± 0.32 | +1.11 ± 0.18 |
| SNX | +1.84 ± 0.41 | +1.11 ± 0.16 | +1.09 ± 0.47 |
| GABRB2 | +2.19 ± 0.33 | +1.97 ± 0.65 | +1.12 ± 0.13 |
| SLC23A2 | −1.11 ± 0.11 | +1.22 ± 0.47 | −1.41 ± 0.03 |
| DIAPH1 | −1.13 ± 0.16 | −2.44 ± 0.18 | −2.01 ± 0.43 |
| LYN | +1.22 ± 0.11 | +.1.77 ± 0.45 | +1.55 ± 0.14 |
| VAMP2 | +1.11 ± 0.12 | +1.25 ± 0.36 | +1.02 ± 0.43 |
(+) – overexpression in comparison to the control; (-) – downregulated in comparison to the control; HRH1- Histamine receptor 1; HRH2 – Histamine receptor 2; HRH3 – Histamine receptor 3; DRD2 – Dopamine Receptor D2; HNMT – Histamine N-methyltransferase; HTR6 – 5-Hydroxytryptamine Receptor 6; GABRB1 – Gamma-aminobutyric acid (GABA) A receptor, alpha 1; GABRB2 – Gamma-aminobutyric acid (GABA) A receptor, alpha 2; GABRB3 – Gamma-aminobutyric acid (GABA) A receptor, alpha 3; EDN1 – Endothelin 1; EDNRA – Endothelin receptor type A; ADA – Adenosine deaminase; SNX – Sorting nexin; SLC223A2 – Solute carrier family 22 member 3; DIAPH1 – diaphanous related formin 1; LYN – LYN Proto-Oncogene, Src Family Tyrosine Kinase; VAMP2 – Vesicle associated membrane protein 2; mean ± standard deviation.